GlaxoSmithKline: Ovarian Neoplasms trials
The registry lists 31 Ovarian Neoplasms studies with GlaxoSmithKline as lead sponsor. 5 are open to participants now and 18 have results posted.
Phase 1 7Phase 2 16Phase 3 7Phase 4 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]RecruitingNCT07694427Phase 3
- A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)RecruitingNCT07684612Phase 3
- A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)RecruitingNCT07286266Phase 3
- A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian CancerNot yet recruitingNCT06887933Phase 4
- A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyRecruitingNCT04641247Phase 2
- A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)TerminatedNCT06964165Phase 2Results posted
- Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian CancerCompletedNCT05751629Phase 2Results posted
- Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian CancerTerminatedNCT03955471Phase 2Results posted
- A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian CancerActive, not recruitingNCT03602859Phase 3Results posted
- A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian CancerCompletedNCT03574779Phase 2Results posted
- Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment PatientsCompletedNCT03359850Phase 1Results posted
- A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyCompletedNCT03326193Phase 2Results posted
- Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid TumorsCompletedNCT03250832Phase 1Results posted
- Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian CancerCompletedNCT02657889Phase 1/2Results posted
- A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyActive, not recruitingNCT02655016Phase 3Results posted
- A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy RegimensCompletedNCT02354586Phase 2Results posted
- A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer PatientsTerminatedNCT01905592Phase 3Results posted
- A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian CancerCompletedNCT01847274Phase 3Results posted
- Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian WomenCompletedNCT01227928Phase 2Results posted
- Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological TumorsCompletedNCT00561795Phase 2Results posted
- Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy ExistsTerminatedNCT00447226Phase 2Results posted
- Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian CancerCompletedNCT00316173Phase 2Results posted
- A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian CancerCompletedNCT00281632Phase 2Results posted
- Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian CancerApproved for marketingNCT03025867
- MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)TerminatedNCT01227941Phase 1
- A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)CompletedNCT00749502Phase 1
- A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid TumorsCompletedNCT00722293Phase 1
- Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian CancerCompletedNCT00659178Phase 1
- Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian CancerCompletedNCT00097409Phase 2
- Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal CancerCompletedNCT00061308Phase 2
- Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian CancerStatus unknownNCT00003733Phase 2